[To learn English]
Swiss drugmaker Novartis said on Monday it had agreed to pay up to $1.5 billion for U.K.-based biotechnology firm Myricx Bio in a deal expected to close in the second half of 2026.
In a statement, Novartis said it would pay $1.1 billion upfront, alongside up to $400 million in potential milestone payments, to acquire London-based Myricx Bio, which develops antibody-drug conjugates used for treating cancer.
瑞士制药商诺华周一宣布，已同意以最高15亿美元收购总部位于英国的生物技术公司Myricx Bio，该交易预计将于2026年下半年完成。
诺华在一份声明中表示，将支付11亿美元预付款，外加最高4亿美元的潜在里程碑付款，以收购这家总部位于伦敦的Myricx Bio。该公司开发用于癌症治疗的抗体药物偶联物。
LearnEnglish Leave a remark